Malaria:
Indications for: DARAPRIM
Treatment of acute malaria in combination with other antimalarials only. Chemoprophylaxis of malaria due to susceptible strains of plasmodia.
Adults and Children:
Acute treatment: Monotherapy not recommended, must give with concomitant fast-acting schizonticides (eg, chloroquine, quinine). 25mg daily for 2 days with a sulfonamide. Monotherapy in semi-immune adult patients (should circumstances arise): 50mg daily for 2 days; children 4–10yrs: 25mg daily for 2 days. Chemoprophylaxis: <4yrs: 6.25mg once weekly. 4–10yrs: 12.5mg once weekly. >10yrs: 25mg once weekly. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, for at least 10 weeks in each case.
DARAPRIM Contraindications:
Megaloblastic anemia due to folate deficiency.
DARAPRIM Warnings/Precautions:
Renal or hepatic impairment. Folate deficiency (eg, malabsorption syndrome, alcoholism, pregnancy, concomitant phenytoin). Pregnancy (Cat.C). Nursing mothers: not recommended.
DARAPRIM Classification:
Folic acid antagonist.
DARAPRIM Interactions:
Increased risk of bone marrow suppression with concomitant antifolic drugs or agents associated with myelosuppression (eg, sulfonamides, trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, methotrexate). Mild hepatotoxicity with lorazepam.
Adverse Reactions:
Hypersensitivity reactions (may be severe: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, anaphylaxis; discontinue if occurs), hyperphenylalaninemia, hematologic effects; rare: pulmonary eosinophilia. May be carcinogenic.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 100
Protozoal infections:
Indications for: DARAPRIM
Treatment of toxoplasmosis when used conjointly with a sulfonamide.
Adult Dosage:
Give concomitant folinic acid. Initially 50–75mg daily, together with 1–4g daily of a sulfonamide of the sulfapyramidine type (eg, sulfadoxine). Continue for 1–3 weeks depending on response and tolerance. May reduce dose by ½ and continue for additional 4–5 weeks.
Children Dosage:
Give concomitant folinic acid and usual pediatric sulfonamide dose. 1mg/kg divided into 2 equal doses; after 2–4 days, may reduce dose by ½ and continue for 1 month.
DARAPRIM Contraindications:
Megaloblastic anemia due to folate deficiency.
DARAPRIM Warnings/Precautions:
Renal or hepatic impairment. Folate deficiency (eg, malabsorption syndrome, alcoholism, pregnancy, concomitant phenytoin); reduce dose or discontinue drug if develops. Seizure disorders: give small starting dose to avoid CNS toxicity. Obtain semi-weekly blood counts, including platelets. Pregnancy (Cat.C). Nursing mothers: not recommended.
DARAPRIM Classification:
Folic acid antagonist.
DARAPRIM Interactions:
Increased risk of bone marrow suppression with concomitant antifolic drugs or agents associated with myelosuppression (eg, sulfonamides, trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, methotrexate). Mild hepatotoxicity with lorazepam.
Adverse Reactions:
Hypersensitivity reactions (may be severe: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, anaphylaxis; discontinue if occurs), hyperphenylalaninemia, hematologic effects (eg, megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, neutropenia), atrophic glossitis, hematuria, cardiac rhythm disorders; rare: pulmonary eosinophilia. May be carcinogenic.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 100
